about
What's new in hepatitis C virus infections in children?The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C.Continuous up to 4 Years Entecavir Treatment of HBV-Infected Adolescents - A Longitudinal Study in Real LifeEvaluation of the effectiveness of treatment with prednisone and azathioprine of autoimmune hepatitis in children.Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4.Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus.Clostridium difficile infection in children hospitalized due to diarrhea.Prophylaxis of vertical HBV infection.Percentage of LFA-1+ and ICAM-1+ peripheral blood mononuclear cells in children and adolescents with type 1 diabetes does not distinguish patients with vascular complications.Acute opercular syndrome in 4-year-old boy.Acute liver failure and liver transplantation in a patient with multiple sclerosis treated with interferon beta.Polish consensus guidelines on the use of acyclovir in the treatment and prevention of VZV and HSV infections.Problems in the diagnosis of profound trichophytosis barbae.Pegylated IFN-α-2a and ribavirin in the treatment of hepatitis C infection in children.The relationship between IL-28B polymorphisms and the response to peginterferon alfa-2a monotherapy in anti-HBe-positive patients with chronic HBV infection.Human meningitis caused by Streptococcus suis.Supplementation with antioxidant vitamins prevents oxidative modification of DNA in lymphocytes of HIV-infected patients.Therapeutic recommendations for 2013: antiviral treatment for chronic hepatitis B.The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B
P50
Q26782000-A3835F70-7F61-4B07-A24E-216CF5CBD9D8Q35675852-B47ECAC5-239A-47B5-BF09-06DD2D1A82A8Q36148535-A42BC7E5-CAA5-4EB2-86D5-04E81D5A679BQ36747135-41400F8A-60E9-42CB-B52A-2F2D469F185BQ36852494-A4D4D035-81C2-4B8F-A080-B7CF0A58CDA4Q37385600-7A1290D1-4E89-46D5-A9F8-70E6322B5E7AQ37411318-6AE0CCEA-8E11-4A39-954A-CC7ADC6629EFQ37534938-3326B782-A8EE-4BE2-8E13-F9E94091E0F4Q38893286-2DD3F32A-BE92-4A22-8181-7ADAAE469AADQ39911101-98F75E71-08E4-4DB8-BC0D-2577632F4D65Q40684199-6AA28696-B81F-4DFD-9676-7F6865CD183FQ40877036-9138C4EC-348C-4208-8034-5B2610D21778Q40880185-81A93674-EA30-40B1-8656-DDDAF9CA3834Q41166845-6F891FD8-EC0C-4633-9ABA-0585B04F5A2AQ41535163-95DE46F6-B8F8-4935-9350-413BAD863549Q42212812-82D049C1-6085-4CCC-8398-644A98DC45B1Q42283357-3B6128B1-4C00-4E92-A855-DD561CCEBBA0Q43895344-159F8D7A-3B7A-483A-A3B7-CBA4BD0938CAQ44781938-3B1F4448-D846-455D-8570-C33C96727CC2Q48033815-48D5AB57-02E8-4407-A5FA-D215E17A5211Q61974430-DDD8CD01-EB74-40AC-A864-815E7B1DD5D5
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Malgorzata Pawlowska
@ast
Malgorzata Pawlowska
@en
Malgorzata Pawlowska
@es
Malgorzata Pawlowska
@nl
Malgorzata Pawlowska
@sl
type
label
Malgorzata Pawlowska
@ast
Malgorzata Pawlowska
@en
Malgorzata Pawlowska
@es
Malgorzata Pawlowska
@nl
Malgorzata Pawlowska
@sl
prefLabel
Malgorzata Pawlowska
@ast
Malgorzata Pawlowska
@en
Malgorzata Pawlowska
@es
Malgorzata Pawlowska
@nl
Malgorzata Pawlowska
@sl
P106
P1153
7004544338
P31
P496
0000-0002-6044-0425